ArticleNature communications2023
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
37.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Tumor Necrosis is Associated with an Increased Metastatic and Cardiovascular Risk in Paragangliomas: A Single-Center Series and Meta-Analysis Comparing Necrosis and Cystic Degeneration in Paragangliomas.Endocrine pathology · 2026Pooled it
- Pooled it
- Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors.Cancer medicine · 2026Review
- Paired genomic profiling of primary tumor and lymph-node metastases identifies candidate prognostic features in penile squamous cell carcinoma.The oncologist · 2026Article
- Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.Endocrine connections · 2026Article
- Genetic alterations of telomere maintenance pathways in paragangliomas.Archives of endocrinology and metabolism · 2026Article
- Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms.Cancers · 2026Review
- Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.Endocrine-related cancer · 2026Review
- The GAPP Aggressivity Score Correlates with Total Enriched Somatic Variant Burden in Sporadic Pheochromocytoma-A Pilot Study.Cancers · 2026Article
- Pheochromocytomas and Paragangliomas.Endocrinology and metabolism clinics of North America · 2026Review
- Multi-omics insights into metastatic pheochromocytomas and paragangliomas: Mechanisms, signatures, and prediction models.Hormones (Athens, Greece) · 2026Review
- Single-Cell Transcriptomic Profiling of Ectopic ACTH-Secreting Pheochromocytoma Reveals the Chromaffin Cell Origin of Ectopic Hormone Production.International journal of molecular sciences · 2026Article
- Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in Succinate Dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas.Molecular biomedicine · 2026Article
- Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution.NPJ precision oncology · 2026Article
- Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarisedCommunications medicine · 2026Article
- Adrenal tumor microenvironment: hormone-immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities.Frontiers in immunology · 2026Review
- SDHB and CDK1 protein expression in metastatic pheochromocytoma and paraganglioma.Endocrine oncology (Bristol, England) · 2026Article
- The evolving roles of pathologists in paragangliomas and pheochromocytomas.Virchows Archiv : an international journal of pathology · 2026Review
- Article
- ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials.ArXiv · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 15 institutions in 6 countries.
Bruna CalsinaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. bcalsina@cnio.es.ORCID 0000-0002-6922-9415
Elena Piñeiro-Yáñez *Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-2773-2343
Ángel M Martínez-Montes *Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-1461-4516
Eduardo CaleirasHistopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Ángel Fernández-SanrománHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-5851-9441
María MonteagudoHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-6280-2987
Rafael Torres-PérezHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-3696-4720
Coral Fustero-TorreBioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0001-5504-4164
Marta Pulgarín-AlfaroHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Eduardo GilHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Rocío LetónHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Scherezade JiménezMonoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Santiago García-MartínBioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-4540-9446
Maria Carmen MartinMolecular Cytogenetics and Genome Engineering Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Juan María Roldán-RomeroHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Javier LanillosHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-5054-6007
Sara MellidHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
María SantosHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Alberto Díaz-TalaveraHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-4279-338X
Ángeles RubioGenomics Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Patricia GonzálezHistopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Barbara HernandoComputational Oncology Group, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Nicole BechmannInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-6932-333X
Margo DonaDepartment of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
María CalatayudDepartment of Endocrinology, 12 de Octubre University Hospital, Madrid, Spain.
Sonsoles GuadalixDepartment of Endocrinology, 12 de Octubre University Hospital, Madrid, Spain.
Cristina Álvarez-EscoláDepartment of Endocrinology, La Paz University Hospital, Madrid, Spain.
Rita M RegojoDepartment of Pathology, La Paz University Hospital, Madrid, Spain.
Javier AllerDepartment of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain.
Maria Isabel Del Olmo-GarciaDepartment of Endocrinology and Nutrition, University Hospital La Fe, Valencia, Spain.
Adrià López-FernándezDepartment of Medical Oncology, Vall d'Hebrón Hospital, Barcelona, Spain.ORCID 0000-0002-2844-5998
Stephanie M J FliednerNeuroendocrine Oncology and Metabolism, Medical Department I, Center of Brain, Behavior, and Metabolism, University Medical Center Schleswig-Holstein Lübeck, Lübeck, Germany.ORCID 0000-0001-5515-8196
Elena RapizziDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Martin FassnachtDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Würzburg, Germany.ORCID 0000-0001-6170-6398
Felix BeuschleinMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.ORCID 0000-0001-7826-3984
Marcus QuinklerEndocrinology in Charlottenburg Stuttgarter Platz 1, Berlin, Germany.
Rodrigo A ToledoGastrointestinal and Endocrine Tumors, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0003-3070-6795
Massimo MannelliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Henri J TimmersDepartment of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
Graeme EisenhoferInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Sandra Rodríguez-PeralesMolecular Cytogenetics and Genome Engineering Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0001-7221-3636
Orlando DomínguezGenomics Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Geoffrey MacintyreComputational Oncology Group, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-3906-467X
Maria Currás-FreixesHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Cristina Rodríguez-AntonaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Alberto CascónHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-2119-891X
Luis J Leandro-GarcíaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Cristina Montero-CondeHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-4452-4469
Giovanna RoncadorMonoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Juan Fernando García-GarcíaDepartment of Pathology, MD Anderson Cancer Center, Madrid, Spain.
Karel PacakSection of Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3541-3767
Fátima Al-ShahrourBioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-2373-769X
Mercedes RobledoHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. mrobledo@cnio.es.ORCID 0000-0001-6256-5902
Spanish National Cancer Research Centre · ESInstituto de Salud Carlos III · ESHospital Universitario La Paz · ESRadboud University Nijmegen · NLResearch Institute Hospital 12 de Octubre · ESUniversity Hospital Carl Gustav Carus · DEUniversity of Florence · ITHospital Universitari i Politècnic La Fe · ESHospital Universitario Puerta de Hierro Majadahonda · ESLMU Klinikum · DEMD Anderson Cancer Center Madrid · ESNational Institutes of Health · USUniversity Hospital Schleswig-Holstein · DEUniversity of Würzburg · DEVall d'Hebron Hospital Universitari · ES
Funding
Diagnosis, Pathophysiology And Molecular Biology of Pheochromocytoma and ParagangliomaZIAHD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2009 to 2024
$28.4MAbstract
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show by genomic profiling of a large cohort of mPPGLs that high mutational load, microsatellite instability and somatic copy-number alteration burden are associated with ATRX/TERT alterations and are suitable prognostic markers. Transcriptomic analysis defines the signaling networks involved in the acquisition of metastatic competence and establishes a gene signature related to mPPGLs, highlighting CDK1 as an additional mPPGL marker. Immunogenomics accompanied by immunohistochemistry identifies a heterogeneous ecosystem at the tumor microenvironment level, linked to the genomic subtype and tumor behavior. Specifically, we define a general immunosuppressive microenvironment in mPPGLs, the exception being PD-L1 expressing MAML3-related tumors. Our study reveals canonical markers for risk of metastasis, and suggests the usefulness of including immune parameters in clinical management for PPGL prognostication and identification of patients who might benefit from immunotherapy.
Indexed as
Adrenal Gland NeoplasmsNeoplasms, Second PrimaryParagangliomaPheochromocytomaGenomicsHumansTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.